Literature DB >> 15914228

Universal influenza A vaccine: optimization of M2-based constructs.

Marina De Filette1, Willy Min Jou, Ashley Birkett, Katie Lyons, Brian Schultz, Anne Tonkyro, Stephanie Resch, Walter Fiers.   

Abstract

M2e is the external domain of the influenza A M2-protein. It is minimally immunogenic during infection and conventional vaccination, which explains in part its striking sequence conservation across all human influenza A strains. Previous research has shown that when M2e is linked to an appropriate carrier such as hepatitis B virus core (HBc) particles, it becomes highly immunogenic, eliciting antibodies that fully protect mice against a potentially lethal virus infection. Different M2e-HBc particles and adjuvants suitable for human use were compared for induction of protective immunity. Strong immunogenicity and full protection were obtained after either intraperitoneal or intranasal administration. The most protective particle contained three consecutive M2e-copies linked to the N-terminus of HBc. Although HBc is highly immunogenic, the optimized M2e-HBc vaccine induced an anti-M2e antibody titer even higher than that of anti-HBc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914228     DOI: 10.1016/j.virol.2005.04.004

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  79 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

Review 2.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

3.  Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.

Authors:  Bao-Zhong Wang; Harvinder S Gill; Sang-Moo Kang; Li Wang; Ying-Chun Wang; Elena V Vassilieva; Richard W Compans
Journal:  Clin Vaccine Immunol       Date:  2012-05-30

4.  Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis.

Authors:  Jamie P Phelps; Nghiep Dang; Lada Rasochova
Journal:  J Virol Methods       Date:  2007-01-16       Impact factor: 2.014

5.  The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.

Authors:  Petr O Ilyinskii; Anatoli B Meriin; Vladimir L Gabai; Evgeny V Usachev; Alexei G Prilipov; Galini Thoidis; Alexander M Shneider
Journal:  Protein Sci       Date:  2008-04-14       Impact factor: 6.725

6.  The Influenza M2 Ectodomain Regulates the Conformational Equilibria of the Transmembrane Proton Channel: Insights from Solid-State Nuclear Magnetic Resonance.

Authors:  Byungsu Kwon; Mei Hong
Journal:  Biochemistry       Date:  2016-09-12       Impact factor: 3.162

7.  Synthesis and characterization of antigenic influenza A M2e protein peptide-poly(acrylic) acid bioconjugate and determination of toxicity in vitro.

Authors:  Yasemin Budama Kilinc; Zeynep Mustafaeva Akdeste; Rabia Cakir Koc; Melahat Bagirova; Adil Allahverdiyev
Journal:  Bioengineered       Date:  2014-11-11       Impact factor: 3.269

8.  A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide.

Authors:  Changgui Li; Bozena Jaentschke; Yingli Song; Junzhi Wang; Terry D Cyr; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  Nat Protoc       Date:  2010-01       Impact factor: 13.491

9.  Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.

Authors:  Attapon Kamlangdee; Brock Kingstad-Bakke; Jorge E Osorio
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

10.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.